A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

Oncogene

Volumn 32, Issue 47, 2013, Pages 5377-5387

  Postel Vinay, S ^a,b   Bajrami, I ^a   Friboulet, L ^b   Elliott, R ^a   Fontebasso, Y ^a   Dorvault, N ^b   Olaussen, K A ^b,c   Andre F ^b,c   Soria, J C ^b,c   Lord, C J ^a   Ashworth, A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

DNA repair; ERCC1; Non small cell lung cancer; PARP1; Synthetic lethality

Indexed keywords

BMN 673; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLYCOSYLTRANSFERASE INHIBITOR; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NIRAPARIB; OLAPARIB; PHARMACOLOGICAL BIOMARKER; RAD51 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER MODEL; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SENSITIVITY; EPISTASIS; G2 PHASE CELL CYCLE CHECKPOINT; GENE LOCUS; HIGH THROUGHPUT SCREENING; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; ENZYME INHIBITORS; G2 PHASE CELL CYCLE CHECKPOINTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDAZOLES; LUNG NEOPLASMS; PHTHALAZINES; PIPERAZINES; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN ISOFORMS; RAD51 RECOMBINASE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84888347956     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.311     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. Cancer J Clin 2009; 59: 225-249
2. Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS et al. Biomarker studies: A call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 2011; 8: 171-176
3. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012; 12: 801-817
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139
5. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019
6. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991
7. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012; 9: 144-155
8. Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E et al. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancer 2012; 118: 2525-2531
9. Vilmar AC, Santoni-Rugiu E, Sorensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010; 21: 1817-1824
10. Fagbemi AF, Orelli B, Scharer OD. Regulation of endonuclease activity in human nucleotide excision repair. DNA Repair 2011; 10: 722-729
11. Kirschner K, Melton DW. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 2010; 30: 3223-3232
12. Tripsianes K, Folkers G, Ab E, Das D, Odijk H, Jaspers NG et al. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 2005; 13: 1849-1858
13. Bergstralh DT, Sekelsky J. Interstrand crosslink repair: Can XPF-ERCC1 be let off the hook? Trends Genet 2008; 24: 70-76
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921
15. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao M, Graziano S et al. ERCC1 isoform expression and DNA repair in non-small cell lung cancer. N Engl J Med 2013; 368: 1101-1110
16. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, Pommier Y. Poly(ADPribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res 2011; 39: 3607-3620
17. Wang B, Chu D, Feng Y, Xin Y, Myers P, Post L et al. Novel PARP inhibitors with potent antitumor activity as single-agent and combination therapies. Mol Cancer Ther 2009; 8(Suppl 12): A121
18. Patterson M, Murray J, Curtin NJ. Stability of PARP inhibition by BMN 673 in human PBMCs and Leukaemic Cell Cultures. Eur J Cancer 2012; 48(Suppl 6): 106 (Abstract 348
19. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. Embo J 2008; 27: 1368-1377
20. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012; 72: 5588-5599
21. Kedar PS, Stefanick DF, Horton JK, Wilson SH. Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol Cancer Res 2012; 10: 360-368
22. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: A systemic review and metaanalysis. Clin Cancer Res 2011; 17: 1632-1640
23. Langer CJ. Exploring biomarkers in head and neck cancer. Cancer 2012; 118: 3882-3892
24. Vilmar AC, Sorensen JB. Customising chemotherapy in advanced nonsmall cell lung cancer: Daily practice and perspectives. Eur Respir Rev 2011; 20: 45-52
25. Metzger R, Bollschweiler E, Holscher AH, Warnecke-Eberz U. ERCC1: Impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol 2010; 6: 1735-1749
26. Steffensen KD, Waldstrom M, Jakobsen A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19: 820-825
27. Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung cancer 2010; 70: 63-70
28. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-2291
29. Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010; 7: 718-724
30. Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011; 17: 875-882
31. Sijbers AM, van der Spek PJ, Odijk H, van den Berg J, van Duin M, Westerveld A et al. Mutational analysis of the human nucleotide excision repair gene ERCC1. Nucleic Acids Res 1996; 24: 3370-3380
32. Dabholkar M, Vionnet J, Parker R, Bostickbruton F, Dobbins A, Reed E. Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes. Oncol Rep 1995; 2: 209-214
33. Sun Y, Li T, Ma K, Tian Z, Zhu Y, Chen F et al. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. Cancer Invest 2009; 27: 891-897
34. Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 2013; 34: 739-749
35. Niedernhofer LJ, Essers J, Weeda G, Beverloo B, de Wit J, Muijtjens M et al. The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells. Embo J 2001; 20: 6540-6549
36. Langelier MF, Planck JL, Roy S, Pascal JM. Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: Structural and functional insights into DNA-dependent PARP-1 activity. J Biol Chem 2011; 286: 10690-10701
37. Langelier MF, Planck JL, Roy S, Pascal JM. Structural basis for DNA damagedependent poly(ADP-ribosyl)ation by human PARP-1. Science 2012; 336: 728-732
38. Bajrami I, Kigozi A, Van Weverwijk A, Brough R, Frankum J, Lord CJ et al. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol Med 2012; 4: 1087-1096
39. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010; 16: 6159-6168
40. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-1115
41. Lord CJ, Martin SA, Ashworth A. RNA interference screening demystified. J Clin Pathol 2009; 62: 195-200